Skip to content

Pharminent

cropped-ChatGPT-Image-Jun-22-2026-05_46_48-PM.png
Primary Menu
  • Home
  • Signal News
  • Biopharma Brief
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Regulatory Interactive Calendar
    • Manufacturing Intelligence
  • Contact
Light/Dark Button
Brief
  • Home
  • Commercial
  • The Rare Journey Needs a Special Pharmacy Partner
  • Commercial

The Rare Journey Needs a Special Pharmacy Partner

Drug Channels

Today's guest post is from Bansi Nagji, Chief Executive Officer at PANTHERx Rare.

CommercialRare DiseaseRead full story

pharminent March 27, 2026 (Last updated: March 30, 2026)

Drug Channels

Today’s guest post is from Bansi Nagji, Chief Executive Officer at PANTHERx Rare.

CommercialRare DiseaseRead full story

Sign up to receive free daily digest

Check your inbox or spam folder to confirm your subscription.

Post navigation

Previous: Merck’s deal for Terns sparks debate over a possible biotech bidding war
Next: Novartis targets Xolair successor in buyout of startup Excellergy

Related Stories

  • Commercial

Post-marketing oncology studies: Enabling faster recruitment and lower costs

pharminent June 22, 2026
  • Commercial

The first 14 days: How specialty programs set patients up for success

pharminent June 22, 2026
  • Commercial

Denali sells FDA voucher for $195M to support neurodegenerative pipeline

pharminent June 19, 2026

You May Have Missed

  • News

pharminent June 22, 2026
sample_feature_2026-06-22
  • News

AbbVie to Acquire Apogee Therapeutics for Nearly $11 Billion in Immunology Bet

pharminent June 22, 2026
  • M&A / Deals

AbbVie climbs post-Allergan M&A peak with Apogee buy

pharminent June 22, 2026
  • M&A / Deals

Lilly bets up to $800M for BioArctic’s brain delivery tech

pharminent June 22, 2026
© 2026 All rights reserved. | ReviewNews by AF themes.